AMTD completes the US IPO of ECMOHO, China’s first online non-medical health and wellness stock

On November 8th, 2019, ECMOHO Limited, ("ECMOHO", Stock Code: NASDAQ:MOHO), a leading non-medical health and wellness integrated solution provider, is successfully listed on the NASDAQ Stock Market. AMTD is the Lead Underwriter and Joint Bookrunner of ECMOHO's IPO and supported the company to successfully land in the international capital market becoming the China’s first online non-medical health and wellness company to be listed in US. This transaction is the 18th IPO deals that AMTD completed in 2019 and the fifth medical and healthcare service company’s IPO that AMTD completed after Henlius Biotech (2696.HK), IVD Medical (1931.HK), IntelliCentrics (6819.HK) and Aptorum Group (NASDAQ: APM).

ECMOHO priced its initial public offering of 4,375,000 American Depositary Shares (“ADSs”) at US$10.00 per ADS. Pre-shoe offering size is US$ 43.75 million and post-shoe offering size is US$ 50.31 million. ECMOHO is China’s largest non-medical health and wellness company as measured by the revenue in 2018 and the first non-medical health and wellness company to be listed in the US stock market. Founded in 2011, ECMOHO is deeply involved in the sector of non-medical health. It mainly purchases high-potential and high-quality products from high-quality brands, guides consumers and expands the market with reliable health information and solutions, and builds an ecosystem of multi-participants such as brand partners, consumers, channel providers, and health experts.

AMTD has been dedicated to serving and connecting capital and resources across Mainland China, Hong Kong and the globe, in order to create a world-class Chinese investment bank. AMTD is aiming to support companies from different regions and industries to develop their business, implement strategic goals and expand their global footprints. AMTD has demonstrated long-term commitment to the healthcare sector. Prior to ECMOHO’s IPO, AMTD successfully assisted Henlius (2696.HK), the largest biotech Hong Kong IPO in 2019 and the leading biopharma company in China; IVD Medical(1931.HK), a leading regional distributor in the China IVD market; IntelliCentrics (6819.HK), a leading medical technology platform; and Aptorum Group (NASDAQ:APM), a leading Hong Kong based medical innovation and biopharmaceutical company, listing on the NASDAQ Stock Exchange and the Main Board of Hong Kong Stock Exchange in the past 12 months.